Morning Overview on MSN
The FDA cleared Xocova, the first oral antiviral to prevent COVID-19 after exposure, in a five-day pill course shown to cut infections in a phase 3 trial
Households where someone tests positive for COVID-19 now have an oral drug option to protect the people around them. The FDA ...
A common response between two types of immune cells during a COVID-19 infection and after initial vaccinations can cause ...
Flow Space on MSN
COVID exposure treatment: What to know about XOCOVA
Why midlife women especially should take note.
The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention ...
The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to ...
The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.
FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments. FDA has approved Shionogi’s Xocova (ensitrelvir) ...
We conducted a phase 2–3 double-blind trial to assess the efficacy and safety of nirmatrelvir–ritonavir in asymptomatic, rapid antigen test–negative adults who had been exposed to a household contact ...
“Got milk? Cure COVID” was a meme that started circulating after one of our discoveries from the University of Florida went public. It playfully highlighted a major medical milestone: We had found a ...
There’s no evidence showing that remdesivir, the first treatment approved for COVID-19, killed patients taking the drug. The antiviral drug is still approved by the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results